Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non–Small Cell Lung Cancer: Emerging Mechanisms and Perspectives

Código QR

Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non–Small Cell Lung Cancer: Emerging Mechanisms and Perspectives

Hiroyuki Inoue,1,2 Isamu Okamoto1 1Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; 2Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, JapanCorrespondence: Isamu OkamotoResearch Institute for Dise...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Inoue H, Okamoto I
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	durvalumab pd-l1 immunogenic cell death lung cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/723fb2720b0041fd8d3e8067056674ad
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick O, et al.
Publicado: (2021)

Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report
por: Albina S. Zhabina, et al.
Publicado: (2021)

Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience
por: Vrankar Martina, et al.
Publicado: (2021)

Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
por: Galina B. Statsenko, et al.
Publicado: (2020)

Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer – A Case Report
por: Li Y, et al.
Publicado: (2021)

New targeted treatments for non-small-cell lung cancer – role of nivolumab
por: Zago G, et al.
Publicado: (2016)

Anti-γ-Aminobutyric Acid Type β Receptor Antibody-Associated Encephalitis After 2 Cycles of Durvalumab Therapy in a Patient with Small Cell Lung Cancer: A Case Report
por: Li J, et al.
Publicado: (2021)

Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
por: Kyoichi Kaira, et al.
Publicado: (2021)

Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives
por: Denis I. Yudin, et al.
Publicado: (2021)

Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors
por: Qi J, et al.
Publicado: (2021)

Spatiotemporally co-delivery of triple therapeutic drugs via HA-coating nanosystems for enhanced immunotherapy
por: Chaoqun Ma, et al.
Publicado: (2021)

The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis
por: He Ba, et al.
Publicado: (2021)

Efficacy of PD‐1/PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China
por: Jiamin Sheng, et al.
Publicado: (2021)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Nathaniel Wiest, et al.
Publicado: (2021)

Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy
por: Taichi Matsubara, et al.
Publicado: (2021)

Safety of thoracic radiotherapy after PD‐(L)1 inhibitor treatment in patients with lung cancer
por: Yu Chen, et al.
Publicado: (2021)

Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
por: Zou W, et al.
Publicado: (2021)

Plasmatic Levels of HSP90α at Diagnosis: A Novel Prognostic Indicator of Clinical Outcome in Advanced Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors Plus Chemotherapy
por: Shubin Chen, et al.
Publicado: (2021)

Antitumor Immune Response Triggered by Metal-Based Photosensitizers for Photodynamic Therapy: Where Are We?
por: Alain C. Jung, et al.
Publicado: (2021)

Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis
por: Yuanfang Xin, et al.
Publicado: (2021)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Di Wang, et al.
Publicado: (2021)

Prognostic implication of PD‐L1 polymorphisms in non‐small cell lung cancer treated with radiotherapy
por: Min Kyu Kang, et al.
Publicado: (2021)

The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report
por: Nikolai A. Ognerubov, et al.
Publicado: (2021)

Kinase Inhibitors’ Effects on Innate Immunity in Solid Cancers
por: Chunying Peng, et al.
Publicado: (2021)

New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
por: Seetharamu N, et al.
Publicado: (2017)

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
por: Xin Cai, et al.
Publicado: (2021)

Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines
por: Yang Wang, et al.
Publicado: (2021)

Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
por: Somasundaram A, et al.
Publicado: (2017)

Dl-3-N-Butylphthalide Presents Anti-Cancer Activity in Lung Cancer by Targeting PD-1/PD-L1 Signaling
por: Jiang Q, et al.
Publicado: (2021)

Clinical Trial Progress and Application of Immune Checkpoint Inhibitors  in the Treatment of Small Cell Lung Cancer
por: Huiqiu ZHANG, et al.
Publicado: (2021)

A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer
por: Yi-Dan Yan, et al.
Publicado: (2021)

Lung cancer international

Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study
por: Qiyi Zhang, et al.
Publicado: (2021)

Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer
por: Ze-Rui Zhao, et al.
Publicado: (2021)

Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma
por: Wen Dong, et al.
Publicado: (2021)

Phase-Transformation Nanoparticle-Mediated Sonodynamic Therapy: An Effective Modality to Enhance Anti-Tumor Immune Response by Inducing Immunogenic Cell Death in Breast Cancer
por: Si Y, et al.
Publicado: (2021)

Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
por: Thakur MK, et al.
Publicado: (2017)

Clinical Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors on NSCLC
por: ZHU Kuikui, et al.
Publicado: (2021)

Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
por: Chi Yan, et al.
Publicado: (2021)

Peritumoral CD90+CD73+ cells possess immunosuppressive features in human non-small cell lung cancer
por: Limei Wang, et al.
Publicado: (2021)